Premium
Harrow Inc (HROW)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Drople... Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits. Show more
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora (NYSE: COR...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a...
Jury in Trademark Infringement Case Finds in Favor of ImprimisRx Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the...
MELT-300 Demonstrates Statistically Superior Compared to Both Sublingual Midazolam (P=0.009) and Placebo (P<0.001) for Providing Successful Procedural Sedation Proportion of Patients Requiring...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th...
Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net loss of $(4.2) million Adjusted EBITDA of $8.8...
New Partnership with GoodRx to Lower Costs for Uninsured and Underinsured Patients Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an innovative...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. Starting...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 14, 2024 Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.59 | 5.30884808013 | 29.95 | 32.97 | 29.5 | 278709 | 31.1465763 | CS |
| 4 | -3.31 | -9.49784791966 | 34.85 | 36.53 | 28.9615 | 320827 | 32.31637825 | CS |
| 12 | -6.295 | -16.6380335668 | 37.835 | 44.45 | 28.9615 | 343200 | 36.07308633 | CS |
| 26 | -4.64 | -12.8247650636 | 36.18 | 59.23 | 28.9615 | 475434 | 42.28086038 | CS |
| 52 | 20.73 | 191.766882516 | 10.81 | 59.23 | 9.3 | 493210 | 29.27205618 | CS |
| 156 | 23.26 | 280.917874396 | 8.28 | 59.23 | 5.4 | 388256 | 20.84856589 | CS |
| 260 | 24.72 | 362.463343109 | 6.82 | 59.23 | 3.33 | 301361 | 17.69754083 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
